The United States of America As Represented by the Department of Health

The United States of America, As Represented by the Secretary, Department of Health and Human Services

University System of Maryland

Other

The United States of America As Represented by the Secretary of

Institut Pasteur

The United States of America

Nobel Biosciences LLC

Hoffmann-la Roche Inc.

Akzo N.v.

Daiichi Pharmaceutical Co., Ltd.

Centocor, Inc.

Virogenetics Corporation

The Government of the United States of America, As Represented by the

Biom&eacute;rieux, Inc.

Robert C Gallo

Mikulas Popovic

Flossie Wong-Staal

Yanto Lunardi-Iskandar

Joseph L Bryant

Luc Montagnier

Jean-Claude Chermann

Solange Chamaret

Francoise Barre-Sinoussi

Christine Rouzioux

Mangalasseril G Sarngadharan

Francoise Rey

Willy Rozenbaum

Claudine Axler-Blin

Charles Dauguet

Marie-Therese Nugeyre

Nancy T Chang

Jacqueline Gruest

Francoise Brun-Vezinet

Genoveffa Franchini

Syed Zaki Salahuddin

George M Shaw

Alfredo Garzino-Demo

Carl W Saxinger

Phillip D Markham

Anthony L Devico

Robert M Crowl

Franco C Lori

Marvin S Reitz, Jr

Suzanne Gartner

Francois Brun-Vezinet

E Prem Reddy

Dharam V Ablashi

Jacques Gruest, Legal Representative

Steven F Josephs

Pierre Sonigo

Marc Alizon

Simon Wain-Hobson

Pierre Tiollais

Stewart T Cole

Oliver Danos

Joseph Bryant

Andrea Cara

Wen-Yi Gao

Franco Lori

Shuji Nakamura

Enzo Paoletti

James Tartaglia

Beatrice H Hahn

William I Cox

Dani Paul Bolognesi

George K Lewis

Noriko G Tanaka

Edgar P Heimer

Thomas James Matthews

Ranajit Pal

Anthony DeVico

Steven Francis Josephs

Marjorie Robert-Guroff

Premkumar E Reddy

Yasuaki Osada

Shinsaku Sakurada

Barbara Ensoli

Fulvia Di Marzo Veronese

Yanto Lundardi-Iskandar

Syed Z Salahuddin

Amanda G Fisher

W Carl Saxinger

G Sarngadharan

Anthony De Vico

Jennifer M Burns

Mangalasseril G Sarngadhar

Kai Krohn

Gerard W Robey

Flossie Wong-Stall

Peter J Fischinger

Annamarie Ranki

Anton A Minassian

The determination of the nucleotide sequence of HIV-1 DNA; identification, isolation and expression of HIV-1 DNA sequences which encode immunoreactive polypeptides by recombinant DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HIV-1.

Cloning and expression of HIV-1 DNA

Disclosed is the molecular cloning of HTLV-III, the adult leukemia and acquired immune deficiency syndrome (AIDS) virus. Clone BH10 contains a 9.0 Kb viral insert constituting the entire HTLV-III genome. Clones BH8 and BH5 contain viral inserts of 5.5 Kb and 3.5 Kb, respectively. These clones are suitable for the development of diagnostic and therapeutic measures for AIDS, as well as use as probes for the detection of AIDS. By scientific convention, HTLV-III, referred to herein also as HIV, has been renamed as HIV-1.

Molecular cloning of HIV-1 from immortalized cell lines

The invention relates to nucleotides encoding therapeutic polypeptides and fragments thereof isolated from beta-human chorionic gonadotropin (&#x3b2;-hCG) found in human early pregnancy urine, now synthetically produced and designated Maternin. The therapeutic polypeptides and their functional equivalents are useful in treating and/or preventing various medical conditions. Examples of therapeutic effects of the therapeutic polypeptides include anti-HIV, anti-cancer, anti-wasting, prohematopoietic (e.g., anemias, radiation-mediated bone marrow damage, and trauma-mediated blood loss), and anti-angiogenic effects. The invention also provides pharmaceutical compositions comprising the therapeutic polypeptides, as well as methods for using the therapeutic polypeptides, functional equivalents and/or pharmaceutical compositions in the treatment and/or prevention of such medical conditions.

Nucleic acids encoding biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)

The determination of the nucleotide sequence of HTLV-III DNA; identification, isolation and expression of HTLV-III sequences which encode immunoreactive polypeptides by recombinant DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HTLV-III.

Cloning and expression of HTLV-III DNA

The invention relates to therapeutic polypeptides isolated from beta-human chorionic gonadotropin (&#x3b2;-hCG) found in human early pregnancy urine, now synthetically produced and designated Maternin. The therapeutic polypeptides and their functional equivalents are useful in treating and/or preventing various medical conditions. Examples of therapeutic effects of the therapeutic polypeptides include anti-HIV, anti-cancer, anti-wasting, prohematopoietic (e.g., anemias, radiation-mediated bone marrow damage, and trauma-mediated blood loss), and anti-angiogenic effects. The invention also provides pharmaceutical compositions comprising the therapeutic polypeptides, as well as methods for using the therapeutic polypeptides, functional equivalents and/or pharmaceutical compositions in the treatment and/or prevention of such medical conditions.

Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)

The present invention relates to compositions and methods of using same to direct an immune response thereby enhancing the efficacy of an antigen containing vaccine by combining a chemokine in conjunction with the vaccine, wherein the choice of the chemokine directs the immune response in either the Th1 or Th2 direction.

Directional induction of immune response by co-administration of antigens with chemokines

This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1) to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates tot he DNA fragments, vectors comprising them and the proteins expressed.

DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1)

This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.

Cloned DNA sequence related to genomic RNA of human immunodeficiency virus (HIV-1)

This invention is in the field of lymphadenopathy virus which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.

Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated virus (LAV) and proteins encoded by said LAV genomic RNA

A new human B lymphotropic virus, also designated human herpesvirus-6, has been isolated. DNA, molecular clones, antigenic viral proteins and antibodies having specificity to the new virus have been prepared. Various utilities of the new virus and products derived therefrom have been described.

Antibodies against human herpes virus-6(HHV-6) and method of use

The present invention relates to fractions of sources and or preparations of human chorionic gonadotropin, such as fractions of human early pregnancy urine, which fractions have anti-HIV activity. The present invention further relates to pharmaceutical compositions comprising such fractions for treating the effects of HIV infection.

Therapeutic fractions of sources of HCG

The present invention relates to peptides of one or more portions of the human chorionic gonadotropin &bgr;-chain as well as methods for treatment of cancer, using human chorionic gonadotropin, employing the &bgr;-chain of human chorionic gonadotropin, peptides containing a sequence of one or more portions of the &bgr;-chain of human chorionic gonadotropin and derivatives and analogues thereof. The invention further relates to fractions of sources and or preparations of human chorionic gonadotropin, such as fractions of human early pregnancy urine, which fractions have anti-cancer activity. The present invention further relates to pharmaceutical compositions for treating cancer.

Method for treating cancer

The present invention relates to &bgr;-hCG, particularly &bgr;-hCG proteins having a sequence of amino acids 41-54, 45-54, 47-53, 45-57 and 45-58 and analogs and derivatives thereof. The invention further relates to methods of treatment and prevention of HIV infection by administration of a therapeutic compound of the invention. Such therapeutic compounds include hCG, &bgr;-hCG and &bgr;-hCG peptides, analogs and derivatives of hCG, &bgr;-hCG and &bgr;-hCG peptides, and nucleic acids encoding hCG, &bgr;-hCG and &bgr;-hCG peptides. In a preferred embodiment, &bgr;-hCG peptides, particularly &bgr;-hCG peptides of amino acids 47-53, 45-57 or 45-58 are administered to a subject for treatment or prevention of HIV infection in that subject. The invention also provides methods for screening hCG preparations for activity in treating or preventing HIV infection. Pharmaceutical compositions and methods of administration of Therapeutics are also provided.

Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin

Growing community of inventors

Bethesda, MD, United States of America

Robert C Gallo